Compare
Johnson & Johnson vs Pfizer (JNJ vs PFE)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Johnson & Johnson (JNJ) returned +48.5% and Pfizer (PFE) +19.4%; so far this year the figures are +33.5% and +18.0%.
Johnson & Johnson is the larger company by market value, about 4.0 times the size of Pfizer.
On trailing earnings, JNJ trades at 41.9 times and PFE at 42.0 times.
Revenue grew +7.8% at JNJ and +1.3% at PFE over the last year.
JNJ yields 1.91%. PFE yields 5.85%.
Data as of the latest close. Not investment advice.
Relative performance
| JNJ | PFE | |
|---|---|---|
| Price | $276.22 | $29.39 |
| 1-day | +1.43% | -1.64% |
| YTD | +33.47% | +18.03% |
| 1 year | +48.51% | +19.42% |
| 3 years | +85.77% | -3.67% |
| Market cap | $665.0B | $167.5B |
| P/E | 41.9 | 42.0 |
| P/S | 6.69 | 2.63 |
| P/B | 8.16 | 1.88 |
| Revenue growth | +7.80% | +1.30% |
| EPS growth | -36.40% | -59.30% |
| Gross margin % | 67.6 | 73.4 |
| Net margin % | 16.2 | 6.3 |
| ROE % | 19.7 | 4.5 |
| Debt / equity | 0.55 | 0.70 |
| FCF yield % | 3.1 | 7.0 |
| Dividend yield % | 1.91 | 5.85 |
| Beta | -0.09 | 0.26 |
| RSI (14) | 59.4 | 49.5 |
| Technical rating |